SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

NVCT

Nuvectis Pharma Inc.
NASDAQHealth Care

Latest close: 18.60 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Aug 21, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 4, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 4, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record2528 flagged findings
Reported transactions (Form 4)40since Jan 2, 2025 · and 3 other holdings
Corporate events (8-K)9since Feb 4, 2022

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-05share offering or dilution eventrecentOpen filing ↗
    “…Public Entity There have been no material changes to the July 2022 Private Placement and the Securities Purchase Agreement, as…”
    +1 more passage from the same document
    • “…as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC…”
  • 2026-05-05listing compliance noticerecentOpen filing ↗
    “…to restore our compliance with NASDAQ’s listing requirements, but we can provide no assurance that any such action taken by us…”
    +1 more passage from the same document
    • “…a delisting, we would likely take actions to restore our compliance with NASDAQ’s listing requirements, but we can provide no…”
  • 2026-02-13share offering or dilution eventrecentOpen filing ↗
    “…Amendment No. 1 to Sales Agreement (“Amendment No. 1”), dated February 13, 2026 (as amended, the “Sales Agreement”). The base…”
    +1 more passage from the same document
    • “…follows this explanatory note. The specific terms of any other securities to be offered pursuant to the base prospectus will…”
  • 2026-02-13capital return (buybacks/dividends)recentOpen filing ↗
    “…liability of its officers or directors to the company or its stockholders for monetary damages for a breach of fiduciary duty as…”
    +1 more passage from the same document
    • “…of the same series; · dates on which interest will accrue or the method for determining dates on which interest will accrue and…”
  • 2026-02-11share offering or dilution eventrecentOpen filing ↗
    “…referred to as the “Private Placement Warrants”. As of December 31, 2025, no additional placement warrants were exercised…”
    +1 more passage from the same document
    • “…placement agent warrants are exercisable. ​ b. At-the-Market Agreement On March 17, 2023, the Company filed a shelf registration…”
  • 2026-02-11listing compliance noticerecentOpen filing ↗
    “…to restore our compliance with NASDAQ’s listing requirements, but we can provide no assurance that any such action taken by us…”
    +1 more passage from the same document
    • “…a delisting, we would likely take actions to restore our compliance with NASDAQ’s listing requirements, but we can provide no…”
  • 2026-02-11Department of Justice inquiryrecentOpen filing ↗
    “…following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 252)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Aug 21, 26S-3 ↗Securities offering
  • Aug 21, 268-K ↗Current report · Other events
  • Aug 6, 26SCHEDULE 13G ↗Passive stake · Soleus Capital Management, L.P. · 5.1% · event on Aug 4, 26
  • Aug 5, 26Form 4 ↗Insider transaction
  • Aug 4, 2610-Q ↗Quarterly report
  • Aug 4, 268-K ↗Current report · Results
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jun 30, 268-K ↗Current report · Entered a material agreement
  • Jun 30, 26424B5 ↗Securities offering
  • Jun 29, 26424B5 ↗Securities offering
  • Jun 29, 268-K ↗Current report · Other events
  • Jun 23, 268-K ↗Current report · Entered a material agreement
  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • Jun 12, 268-K ↗Current report · Shareholder vote results
  • May 5, 2610-Q ↗Quarterly report
  • May 5, 268-K ↗Current report · Results
  • Apr 27, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 27, 26DEF 14A ↗Shareholder meeting and votes
  • Feb 18, 26CORRESP ↗Correspondence with the SEC
  • Feb 18, 26UPLOAD ↗Correspondence with the SEC
  • Feb 13, 26S-3 ↗Securities offering

252 filings on record, the oldest from Aug 26, 21.

Listing the 25 most recent filings of the 252 on record.

8-Ks, explained

Structure6Governance3
  • Jun 30, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 23, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Sep 25, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Feb 6, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jun 16, 23GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jul 29, 22StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Mar 22, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 4, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Soleus Capital Management, L.P.5.1%Aug 4, 26SCHEDULE 13G ↗9 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jun 30, 26Buy$250KRON BENTSURChairman & CEO↗
  • Jun 30, 26Buy$916KMarlio Charles Mosseri↗
  • Nov 5, 25Buy$64KMatthew L. Kaplan↗
  • Nov 5, 25Buy$75KJuan Sanchez↗
  • Nov 5, 25Buy$29KRON BENTSURChairman & CEO↗
  • Oct 27, 25Buy$457KMarlio Charles Mosseri↗
  • Oct 24, 25Buy$215KMarlio Charles Mosseri↗
  • Oct 23, 25Buy$284KMarlio Charles Mosseri↗
  • Jun 20, 25Buy$45KMarlio Charles Mosseri↗
  • Jun 18, 25Buy$226KMarlio Charles Mosseri↗
  • Jun 17, 25Buy$44KMarlio Charles Mosseri↗
  • May 12, 25Buy$172KMarlio Charles Mosseri↗

There are 14 more transactions in this stretch.

Stock compensation, tax and giftsshow the 14 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 3, 26Compensationamount n/aMichael J. CarsonVice President, Finance↗
  • Jun 11, 26Compensationamount n/aMatthew L. Kaplan↗
  • Jun 11, 26Compensationamount n/aJuan Sanchez↗
  • Jun 11, 26Compensationamount n/aJames F Oliviero III↗
  • Jun 11, 26Compensationamount n/aKenneth Hoberman↗
  • Jan 6, 26Compensationamount n/aMichael J. CarsonVice President, Finance↗
  • Jan 6, 26Compensationamount n/aEnrique PoradosuChief Science & Business Off↗
  • Jan 6, 26Compensationamount n/aRON BENTSURChairman & CEO↗
  • Jan 6, 26Compensationamount n/aShay ShemeshChief Dev. & Ops. Officer↗
  • Sep 22, 25Compensationamount n/aJuan Sanchez↗
  • Jun 12, 25Compensationamount n/aKenneth Hoberman↗
  • Jun 12, 25Compensationamount n/aJames F Oliviero III↗
  • Jun 12, 25Compensationamount n/aMatthew L. Kaplan↗
  • Jan 2, 25Compensationamount n/aRON BENTSURChairman & CEO↗

The full record holds 116 transactions and goes back to Jan 3, 23.

Its sector and its market

Nuvectis Pharma Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Nuvectis Pharma Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Nuvectis Pharma Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
252 documents on file, from Aug 26, 2021 to Aug 21, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.

Nuvectis Pharma Inc. (NVCT): stock price history, insider trades and SEC filings — HornScout